In this talk, we will cover:
Application of synthetic biology alongside computational methodologies to improve the efficiency and stability of lentiviral vector production.
Development of clonal, suspension HEK293T-based packaging and producer cell lines for the inducible production of VSV-G pseudotyped lentiviral vectors, aiming to simplify the manufacturing process.
Achievement of mid-E8 TU/mL titers across multiple CAR transgenes through engineered plasmids for tightly regulated gene expression and the use of a proprietary hyperactive transposase.
The strategic advantages provided by the LV Edge System, including scalability, reduced process complexity, and the elimination of the need for GMP-grade plasmids, potentially leading to more cost-effective cell and gene therapies.